{
    "organizations": [],
    "uuid": "2cec8eb6ff9d43018357700984dd99e93da7268a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-krystal-submits-investigational-ne/brief-krystal-submits-investigational-new-drug-application-for-kb103-idUSFWN1R90B1",
    "ord_in_thread": 0,
    "title": "BRIEF-Krystal Submits Investigational New Drug (Ind) Application For KB103",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 27 (Reuters) - Krystal Biotech Inc:\n* KRYSTAL SUBMITS INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR KB103, TOPICAL GENE THERAPY CANDIDATE FOR DYSTROPHIC EPIDERMOLYSIS BULLOSA\n* KRYSTAL BIOTECH - THERAPEUTIC CANDIDATE FORMULATED INTO A TOPICAL GEL FOR DIRECT APPLICATION ONTO SKIN Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)\n ",
    "published": "2018-03-27T20:03:00.000+03:00",
    "crawled": "2018-03-28T19:16:20.033+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "krystal",
        "biotech",
        "inc",
        "krystal",
        "submits",
        "investigational",
        "new",
        "drug",
        "ind",
        "application",
        "kb103",
        "topical",
        "gene",
        "therapy",
        "candidate",
        "dystrophic",
        "epidermolysis",
        "bullosa",
        "krystal",
        "biotech",
        "therapeutic",
        "candidate",
        "formulated",
        "topical",
        "gel",
        "direct",
        "application",
        "onto",
        "skin",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}